• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by PharmaCyte Biotech Inc. (Amendment)

    6/16/23 5:22:36 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PMCB alert in real time by email
    SC 13D/A 1 sc13da507004013_06162023.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 5)1

    PharmaCyte Biotech, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    717512X203

    (CUSIP Number)

    RICHARD ABBE

    IROQUOIS CAPITAL MANAGEMENT, LLC

    2 Overhill Road, Suite 400

    Scarsdale, New York 10583

    (212) 974-3070

     

    ANDREW FREEDMAN, ESQ.

    MATTHEW W. TRAYLOR, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    June 15, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 717512X203

      1   NAME OF REPORTING PERSON  
             
            Iroquois Master Fund Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%*  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * The Series A Warrants, the Common Stock Warrants, the Private Placement Warrants (collectively, the “Warrants”) and the Preferred Shares (as defined below) held by certain of the Reporting Persons are subject to a 4.99% blocker and the percentage set forth in row (13) gives effect to such blocker. However, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (8), (10) and (11).

    2

    CUSIP No. 717512X203

      1   NAME OF REPORTING PERSON  
             
            Iroquois Capital Management, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * The Series A Warrants, the Common Stock Warrants, the Private Placement Warrants (collectively, the “Warrants”) and the Preferred Shares held by certain of the Reporting Persons are subject to a 4.99% blocker and the percentage set forth in row (13) gives effect to such blocker. However, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (8), (10) and (11).

    3

    CUSIP No. 717512X203

     

      1   NAME OF REPORTING PERSON  
             
            Iroquois Capital Investment Group LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         10,696 shares of Common Stock
    384,000 shares of Common Stock issuable upon exercise of Warrants*
    300,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              10,696 shares of Common Stock
    384,000 shares of Common Stock issuable upon exercise of Warrants*
    300,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            10,696 shares of Common Stock
    384,000 shares of Common Stock issuable upon exercise of Warrants*
    300,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * The Series A Warrants, the Common Stock Warrants, the Private Placement Warrants (collectively, the “Warrants”) and the Preferred Shares held by certain of the Reporting Persons are subject to a 4.99% blocker and the percentage set forth in row (13) gives effect to such blocker. However, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (8), (10) and (11).

    4

    CUSIP No. 717512X203

     

      1   NAME OF REPORTING PERSON  
             
            Richard Abbe  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         10,696 shares of Common Stock
    384,000 shares of Common Stock issuable upon exercise of Warrants*
    300,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              10,696 shares of Common Stock
    384,000 shares of Common Stock issuable upon exercise of Warrants*
    300,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
        10   SHARED DISPOSITIVE POWER  
               
              178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
           

    189,350 shares of Common Stock

    2,280,000 shares of Common Stock issuable upon exercise of Warrants*

    2,000,000 shares of Common Stock issuable upon exercise of Preferred Shares*

     
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    * The Series A Warrants, the Common Stock Warrants, the Private Placement Warrants (collectively, the “Warrants”) and the Preferred Shares held by certain of the Reporting Persons are subject to a 4.99% blocker and the percentage set forth in row (13) gives effect to such blocker. However, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (8), (10) and (11).

    5

    CUSIP No. 717512X203

     

      1   NAME OF REPORTING PERSON  
             
            Kimberly Page  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            178,654 shares of Common Stock
    1,896,000 shares of Common Stock issuable upon exercise of Warrants*
    1,700,000 shares of Common Stock issuable upon exercise of Preferred Shares*
     
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            4.99%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    * The Series A Warrants, the Common Stock Warrants, the Private Placement Warrants (collectively, the “Warrants”) and the Preferred Shares held by certain of the Reporting Persons are subject to a 4.99% blocker and the percentage set forth in row (13) gives effect to such blocker. However, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (8), (10) and (11).

    6

    CUSIP No. 717512X203

    The following constitutes Amendment No. 5 to the Schedule 13D filed by the undersigned (“Amendment No. 5”). This Amendment No. 5 amends the Schedule 13D as specifically set forth herein.

     

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

     

    The Shares and Series A and Common Stock Warrants purchased by Iroquois Master Fund and ICIG were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 178,654 Shares and Series A and Common Stock Warrants to acquire 196,000 Shares beneficially owned by Iroquois Master Fund and Iroquois Capital was approximately $531,016.22, including brokerage commissions.

     

    The aggregate purchase price of the 10,696 Shares and Series A and Common Stock Warrants to acquire 84,000 Shares beneficially owned by ICIG was approximately $30,851.54, including brokerage commissions.

     

    As further described in Item 6 of this Schedule 13D, pursuant to the Purchase Agreement, at the Closing Date: (i) Iroquois Master Fund purchased 6,800 Preferred Shares convertible into 1,700,000 Shares and 1,700,000 Private Placement Warrants to purchase up to 1,700,000 Shares for approximately $6,800,000 and (ii) Iroquois Capital purchased 1,200 Preferred Shares convertible into 300,000 Shares and 300,000 Private Placement Warrants to purchase up to 300,000 Shares for $1,200,000.

     

    Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise any of the Warrants or convert any of the Preferred Shares if the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding Shares (the “Blocker”), and the percentage set forth in Row 13 of the cover page for each Reporting Person gives effect to the applicable Blocker.

     

    Item 5.Interest in Securities of the Issuer.

     

    Items 5(a) – (c) and (e) are hereby amended and restated to read as follows:

    The aggregate percentage of Shares reported owned by each person named herein is based upon 8,708,101 Shares, which represents the number of Shares issued and outstanding as of June 9, 2023, as represented in the Issuer’s Amendment No. 1 to Schedule TO, filed with the SEC on June 15, 2023.

    For purposes of calculating the percentages, the Reporting Persons’ beneficial ownership includes securities of the Issuer subject to the Blocker described in Item 3 of this Schedule 13D, which includes an aggregate of 4,280,000 Shares underlying certain securities owned by the Reporting Persons, consisting of (i) 2,280,000 Shares issuable upon exercise of Warrants and (ii) 2,000,000 Shares issuable upon exercise of Preferred Shares.

     

    A.Iroquois Master Fund
    (a)As of the close of business on June 16, 2023, Iroquois Master Fund may be deemed the beneficial owner of (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares.

    Percentage: Approximately 4.99%

    7

    CUSIP No. 717512X203

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and 1,700,000 Shares issuable upon exercise of Preferred Shares.
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and 1,700,000 Shares issuable upon exercise of Preferred Shares.

     

    (c)The transactions in the Shares entered into by Iroquois Master Fund since Amendment No. 4 are set forth in Schedule A and are incorporated herein by reference.
    (e)On June 15, 2023, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.

    B.Iroquois Capital
    (a)As of the close of business on June 16, 2023, Iroquois Capital, as the investment manager to Iroquois Master Fund, may be deemed the beneficial owner of the (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares.

    Percentage: Approximately 4.99%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares

     

    (c)Iroquois Capital has not entered into any transactions in the Shares since the filing of Amendment No. 4 to the Schedule 13D. The transactions in the Shares entered into by Iroquois Master Fund since Amendment No. 4 are set forth in Schedule A and are incorporated herein by reference.
    (e)On June 15, 2023, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.

    C.ICIG
    (a)As of the close of business on June 16, 2023, ICIG may be deemed the beneficial owner of i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares.

    Percentage: 4.99%

    (b)1. Sole power to vote or direct vote: (i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: (i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares
    4. Shared power to dispose or direct the disposition: 0

     

    (c)ICIG has not entered into any transactions in the Shares since the filing of Amendment No. 4 to the Schedule 13D.
    8

    CUSIP No. 717512X203

    (e)On June 15, 2023, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.

    E.Richard Abbe
    (a)As of the close of business on June 16, 2023, Mr. Abbe, as the managing member of ICIG, may be deemed the beneficial owner of the i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares owned by ICIG. Mr. Abbe, as the President of Iroquois Capital, may be deemed the beneficial owner of the (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund.

    Percentage: Approximately 4.99%

    (b)1. Sole power to vote or direct vote: (i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares owned by ICIG
    2. Shared power to vote or direct vote: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund
    3. Sole power to dispose or direct the disposition: (i) 10,696 Shares, (ii) 384,000 Shares issuable upon exercise of Warrants and (iii) 300,000 Shares issuable upon exercise of Preferred Shares owned by ICIG
    4. Shared power to dispose or direct the disposition: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund

     

    (c)Mr. Abbe has not entered into any transactions in the Shares since the filing of Amendment No. 4 to the Schedule 13D. The transactions in the Shares entered into by Iroquois Master Fund since Amendment No. 4 are set forth in Schedule A and are incorporated herein by reference.
    (e)On June 15, 2023, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.

    F.Kimberly Page
    (a)As of the close of business on June 16, 2023, Mrs. Page, as a Director of Iroquois Master Fund, may be deemed the beneficial owner of the: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund.

    Percentage: Approximately 4.99%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: (i) 178,654 Shares, (ii) 1,896,000 Shares issuable upon exercise of Warrants and (iii) 1,700,000 Shares issuable upon exercise of Preferred Shares owned by Iroquois Master Fund

     

    (c)Mrs. Page has not entered into any transactions in the Shares since the filing of Amendment No. 4 to the Schedule 13D. The transactions in the Shares entered into by Iroquois Master Fund since Amendment No. 4 are set forth in Schedule A and are incorporated herein by reference.
    (e)On June 15, 2023, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares of the Issuer.
    9

    CUSIP No. 717512X203

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    Pursuant to a cash self-tender offer (the “Tender Offer”) conducted by the Issuer to purchase up to 7,750,000 Shares in accordance with the Offer to Purchase, dated May 11, 2023, by and among the Issuer and the stockholders of the Issuer, including the Reporting Persons, the Reporting Persons tendered, in exchange for cash consideration of $3.25 per share, all of the Shares beneficially owned by them. Because the Tender Offer was oversubscribed, the Company purchased only a prorated portion (approximately 83%) of the Shares properly tendered by stockholders. Therefore, 1,047,365 Shares tendered by the Reporting Persons were accepted by the Issuer on June 9, 2023.

    10

    CUSIP No. 717512X203

    SIGNATURES

    After reasonable inquiry and to the best of his or her knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: June 16, 2023

      IROQUOIS MASTER FUND LTD.
       
      By: Iroquois Capital Management, LLC,
        its investment manager
         
      By:

    /s/ Richard Abbe

        Name: Richard Abbe
        Title: President

     

     

      IROQUOIS CAPITAL MANAGEMENT, LLC
       
      By:

    /s/ Richard Abbe

        Name: Richard Abbe
        Title: President

     

     

      IROQUOIS CAPITAL INVESTMENT GROUP LLC
       
      By:

    /s/ Richard Abbe

        Name: Richard Abbe
        Title: Managing Member

     

     

     

    /s/ Richard Abbe

      RICHARD ABBE

     

     

     

    /s/ Kimberly Page

      KIMBERLY PAGE

     

    11

    CUSIP No. 717512X203

    SCHEDULE A

    Transactions in the Securities of the Issuer during the Past Sixty Days

    Nature of the Transaction

    Amount of Securities

    Purchased/(Sold)

    Price ($)

    Date of

    Purchase/Sale

     

    IROQUOIS MASTER FUND LTD.

    Sale of Common Stock 5,900 3.03 6/16/2023

     

    Get the next $PMCB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMCB

    DatePrice TargetRatingAnalyst
    11/8/2021Neutral
    HC Wainwright & Co.
    More analyst ratings

    $PMCB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

      Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • MyMD Pharmaceuticals Secures Strategic Investments

      Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PMCB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on PharmaCyte Biotech

      HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral

      11/8/21 6:05:27 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weinstein Robert

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:59:12 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walker Wayne Remell

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:59 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schechter Jonathan

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:49 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    SEC Filings

    See more
    • PharmaCyte Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      4/24/25 4:47:19 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by PharmaCyte Biotech Inc.

      10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/17/25 5:22:56 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by PharmaCyte Biotech Inc.

      DEFA14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/10/25 4:18:48 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Leadership Updates

    Live Leadership Updates

    See more
    • Oblong Appoints Two New Directors to its Board

      Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

      5/30/23 8:00:00 AM ET
      $OBLG
      $PMCB
      $PTPI
      $SNPX
      Computer Software: Programming Data Processing
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

      Company Appoints Five New Independent Directors to Reconstituted Board PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte's outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois' director designees to PharmaCyte's reconstituted Board of Directors. Pursuant to the Agreement, Iroquois' director designees, Jonathan L. Schechter and Jo

      8/15/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

      PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022. Cash Position PharmaCyte had $85.4 million in cash and cash equivalents as of April 30, 2022. Preliminary (Unaudited) 2022 Fiscal Year End Financial Results PharmaCyte expects to report operating expenses of approximately $4.4 million, compared to $3.6 million in the prior fiscal year. This increase is primarily due to expenses associated with PharmaCyte listing on Nasdaq an

      7/11/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Financials

    Live finance-specific insights

    See more
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

      Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly Conference Calls Questions the Board and Management's Alignment with Shareholders Given Minimal Stock Ownership and Failure to Purchase Shares in the Open Market Calls on the Company to Actively Enlist Shareholder Participation in a Process to Refresh a Majority of the Directors on the Board with Highly Qualified Candidates to Fill Gaps in the Existing Leadership's Skillset and Bring Fresh Perspecti

      5/11/22 9:00:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PharmaCyte Biotech Inc.

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      11/13/24 11:19:35 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PharmaCyte Biotech Inc.

      SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/14/24 3:38:38 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by PharmaCyte Biotech Inc. (Amendment)

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/6/24 9:56:28 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care